Synsam AB

ST:SYNSAM Sweden Medical Instruments & Supplies
Market Cap
$858.57 Million
Skr9.63 Billion SEK
Market Cap Rank
#8578 Global
#62 in Sweden
Share Price
Skr67.70
Change (1 day)
+0.74%
52-Week Range
Skr41.05 - Skr70.00
All Time High
Skr70.00
About

Synsam AB (publ), together with its subsidiaries, operates in the optical retail and eye health sector in the Nordic Region. The company offers lenses, frames, sunglasses, sports spectacles, contact lenses, eye care accessories, and hearing aids. It also provides eye health services, hearing tests, lifestyle subscriptions, contact lens subscriptions, personal style advice services, and eye examin… Read more

Synsam AB (SYNSAM) - Net Assets

Latest net assets as of September 2025: Skr2.46 Billion SEK

Based on the latest financial reports, Synsam AB (SYNSAM) has net assets worth Skr2.46 Billion SEK as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr7.88 Billion) and total liabilities (Skr5.42 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr2.46 Billion
% of Total Assets 31.27%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change N/A
Growth Volatility 2.83

Synsam AB - Net Assets Trend (2018–2024)

This chart illustrates how Synsam AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Synsam AB (2018–2024)

The table below shows the annual net assets of Synsam AB from 2018 to 2024.

Year Net Assets Change
2024-12-31 Skr2.56 Billion +1.55%
2023-12-31 Skr2.52 Billion -2.63%
2022-12-31 Skr2.58 Billion +4.24%
2021-12-31 Skr2.48 Billion +257.44%
2020-12-31 Skr-1.57 Billion -14.78%
2019-12-31 Skr-1.37 Billion -14.63%
2018-12-31 Skr-1.20 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Synsam AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 24330000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock Skr1.00 Million 0.04%
Other Comprehensive Income Skr112.00 Million 4.38%
Other Components Skr4.31 Billion 168.53%
Total Equity Skr2.56 Billion 100.00%

Synsam AB Competitors by Market Cap

The table below lists competitors of Synsam AB ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Synsam AB's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 2,516,000,000 to 2,555,000,000, a change of 39,000,000 (1.6%).
  • Net income of 366,000,000 contributed positively to equity growth.
  • Dividend payments of 266,000,000 reduced retained earnings.
  • Share repurchases of 85,000,000 reduced equity.
  • Other comprehensive income increased equity by 17,000,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income Skr366.00 Million +14.32%
Dividends Paid Skr266.00 Million -10.41%
Share Repurchases Skr85.00 Million -3.33%
Other Comprehensive Income Skr17.00 Million +0.67%
Other Changes Skr7.00 Million +0.27%
Total Change Skr- 1.55%

Book Value vs Market Value Analysis

This analysis compares Synsam AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.91x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2018-12-31 Skr-7.98 Skr67.70 x
2019-12-31 Skr-9.15 Skr67.70 x
2020-12-31 Skr-10.50 Skr67.70 x
2021-12-31 Skr16.53 Skr67.70 x
2022-12-31 Skr17.25 Skr67.70 x
2023-12-31 Skr16.88 Skr67.70 x
2024-12-31 Skr17.30 Skr67.70 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Synsam AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 14.32%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 5.69%
  • • Asset Turnover: 0.78x
  • • Equity Multiplier: 3.23x
  • Recent ROE (14.32%) is above the historical average (5.92%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2018 0.00% -8.78% 0.53x 0.00x Skr-179.93 Million
2019 0.00% -4.71% 0.55x 0.00x Skr-40.82 Million
2020 0.00% -5.06% 0.53x 0.00x Skr-37.74 Million
2021 2.06% 1.08% 0.62x 3.07x Skr-196.90 Million
2022 12.69% 6.13% 0.67x 3.10x Skr69.60 Million
2023 12.36% 5.27% 0.73x 3.19x Skr59.40 Million
2024 14.32% 5.69% 0.78x 3.23x Skr110.50 Million

Industry Comparison

This section compares Synsam AB's net assets metrics with peer companies in the Medical Instruments & Supplies industry.

Industry Context

  • Industry: Medical Instruments & Supplies
  • Average net assets among peers: $376,322,575
  • Average return on equity (ROE) among peers: -23.29%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Synsam AB (SYNSAM) Skr2.46 Billion 0.00% 2.20x $731.69 Million
AddLife AB (publ) (ALIF-B) $1.89 Billion 27.39% 1.20x $1.42 Billion
Biotage AB (BIOT) $476.77 Million 8.68% 0.24x $787.18 Million
Bonesupport Holding AB (BONEX) $124.31 Million -129.56% 0.58x $897.79 Million
Dynavox Group (DYVOX) $210.60 Million 23.08% 5.28x $786.85 Million
iZafe Group AB Series B (IZAFE-B) $9.04 Million -35.07% 0.67x $12.58 Million
Ortivus AB ser. A (ORTI-A) $84.63 Million -21.84% 0.94x $1.20 Million
S2Medical AB (S2M) $25.11 Million -73.41% 0.22x $641.00K
Stille AB (STIL) $189.81 Million 14.40% 0.80x $82.32 Million